Joseph Michael Fitzgerald - 16 Feb 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: EVP & Group Pres, Cardiology
Signature: /s/ Susan Thompson, Attorney-in-Fact
Issuer symbol: BSX
Transactions as of: 16 Feb 2023
Transactions value $: -$264,751
Form type: 4
Filing time: 21 Feb 2023, 15:19:10 UTC
Previous filing: 21 Feb 2023
Next filing: 22 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BSX	Common Stock	Options Exercise	$0	+3.96K	+1.87%	$0.00	216K	16 Feb 2023	Direct	F1
transaction	BSX	Common Stock	Tax liability	-$83.9K	-1.81K	-0.84%	$46.48	214K	16 Feb 2023	Direct
transaction	BSX	Common Stock	Options Exercise	$0	+4.17K	+1.94%	$0.00	218K	17 Feb 2023	Direct	F1
transaction	BSX	Common Stock	Tax liability	-$95.7K	-2.06K	-0.94%	$46.54	216K	17 Feb 2023	Direct
transaction	BSX	Common Stock	Options Exercise	$0	+3.71K	+1.71%	$0.00	220K	18 Feb 2023	Direct	F2
transaction	BSX	Common Stock	Tax liability	-$85.1K	-1.83K	-0.83%	$46.54	218K	18 Feb 2023	Direct
holding	BSX	Common Stock						68.1K	16 Feb 2023	By 401(k)	F3
holding	BSX	Common Stock						4.34K	16 Feb 2023	By Child	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Restricted Stock Units	Options Exercise	$0	-3.96K	-25%	$0.00	11.9K	16 Feb 2023	Common Stock	3.96K		Direct	F1, F5
transaction	BSX	Restricted Stock Units	Options Exercise	$0	-4.17K	-33.33%	$0.00	8.33K	17 Feb 2023	Common Stock	4.17K		Direct	F1, F6
transaction	BSX	Deferred Stock Units	Options Exercise	$0	-3.71K	-50%	$0.00	3.71K	18 Feb 2023	Common Stock	3.71K		Direct	F2, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2	Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.
F3	Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F4	The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F5	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
F6	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.
F7	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.